vs

Side-by-side financial comparison of Fathom Holdings Inc. (FTHM) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Fathom Holdings Inc. is the larger business by last-quarter revenue ($90.6M vs $70.6M, roughly 1.3× Viridian Therapeutics, Inc.\DE). Fathom Holdings Inc. runs the higher net margin — -7.4% vs -49.0%, a 41.6% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -1.2%). Fathom Holdings Inc. produced more free cash flow last quarter ($-20.7M vs $-84.7M).

Fathom Holdings Inc. is a US-based real estate technology and services enterprise. It provides end-to-end solutions for real estate agents, brokers, and consumers, including digital transaction management tools, mortgage services, title insurance, and residential property brokerage services, covering most regional markets across the United States.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

FTHM vs VRDN — Head-to-Head

Bigger by revenue
FTHM
FTHM
1.3× larger
FTHM
$90.6M
$70.6M
VRDN
Growing faster (revenue YoY)
VRDN
VRDN
+81959.4% gap
VRDN
81958.1%
-1.2%
FTHM
Higher net margin
FTHM
FTHM
41.6% more per $
FTHM
-7.4%
-49.0%
VRDN
More free cash flow
FTHM
FTHM
$64.1M more FCF
FTHM
$-20.7M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FTHM
FTHM
VRDN
VRDN
Revenue
$90.6M
$70.6M
Net Profit
$-6.7M
$-34.6M
Gross Margin
Operating Margin
-5.2%
-56.7%
Net Margin
-7.4%
-49.0%
Revenue YoY
-1.2%
81958.1%
Net Profit YoY
-7.7%
54.9%
EPS (diluted)
$-0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FTHM
FTHM
VRDN
VRDN
Q4 25
$90.6M
Q3 25
$115.3M
$70.6M
Q2 25
$121.4M
Q1 25
$93.1M
Q4 24
$91.7M
Q3 24
$83.7M
Q2 24
$89.2M
Q1 24
$70.5M
Net Profit
FTHM
FTHM
VRDN
VRDN
Q4 25
$-6.7M
Q3 25
$-4.4M
$-34.6M
Q2 25
$-3.6M
Q1 25
$-5.6M
Q4 24
$-6.2M
Q3 24
$-8.1M
Q2 24
$-1.3M
Q1 24
$-5.9M
Operating Margin
FTHM
FTHM
VRDN
VRDN
Q4 25
-5.2%
Q3 25
-3.5%
-56.7%
Q2 25
-2.0%
Q1 25
-4.8%
Q4 24
-7.0%
Q3 24
-9.3%
Q2 24
-4.1%
Q1 24
-8.0%
Net Margin
FTHM
FTHM
VRDN
VRDN
Q4 25
-7.4%
Q3 25
-3.8%
-49.0%
Q2 25
-3.0%
Q1 25
-6.1%
Q4 24
-6.8%
Q3 24
-9.7%
Q2 24
-1.5%
Q1 24
-8.4%
EPS (diluted)
FTHM
FTHM
VRDN
VRDN
Q4 25
$-0.20
Q3 25
$-0.15
Q2 25
$-0.13
Q1 25
$-0.24
Q4 24
$-0.29
Q3 24
$-0.40
Q2 24
$-0.07
Q1 24
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FTHM
FTHM
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$5.8M
$490.9M
Total DebtLower is stronger
$5.6M
Stockholders' EquityBook value
$37.4M
$503.0M
Total Assets
$78.0M
$577.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FTHM
FTHM
VRDN
VRDN
Q4 25
$5.8M
Q3 25
$9.8M
$490.9M
Q2 25
$4.9M
Q1 25
$8.0M
Q4 24
$7.1M
Q3 24
$13.1M
Q2 24
$10.4M
Q1 24
$5.7M
Total Debt
FTHM
FTHM
VRDN
VRDN
Q4 25
$5.6M
Q3 25
$5.1M
Q2 25
$5.1M
Q1 25
$5.1M
Q4 24
$9.5M
Q3 24
$8.8M
Q2 24
$3.6M
Q1 24
$3.7M
Stockholders' Equity
FTHM
FTHM
VRDN
VRDN
Q4 25
$37.4M
Q3 25
$43.4M
$503.0M
Q2 25
$40.7M
Q1 25
$43.4M
Q4 24
$44.7M
Q3 24
$47.1M
Q2 24
$53.1M
Q1 24
$51.9M
Total Assets
FTHM
FTHM
VRDN
VRDN
Q4 25
$78.0M
Q3 25
$83.2M
$577.1M
Q2 25
$80.4M
Q1 25
$81.0M
Q4 24
$75.4M
Q3 24
$80.9M
Q2 24
$80.2M
Q1 24
$78.2M
Debt / Equity
FTHM
FTHM
VRDN
VRDN
Q4 25
0.15×
Q3 25
0.12×
Q2 25
0.12×
Q1 25
0.12×
Q4 24
0.21×
Q3 24
0.19×
Q2 24
0.07×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FTHM
FTHM
VRDN
VRDN
Operating Cash FlowLast quarter
$-20.5M
$-84.6M
Free Cash FlowOCF − Capex
$-20.7M
$-84.7M
FCF MarginFCF / Revenue
-22.8%
-120.1%
Capex IntensityCapex / Revenue
0.1%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-29.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FTHM
FTHM
VRDN
VRDN
Q4 25
$-20.5M
Q3 25
$3.0M
$-84.6M
Q2 25
$-5.9M
Q1 25
$-5.7M
Q4 24
$-4.7M
Q3 24
$-330.0K
Q2 24
$-3.1M
Q1 24
$-947.0K
Free Cash Flow
FTHM
FTHM
VRDN
VRDN
Q4 25
$-20.7M
Q3 25
$3.0M
$-84.7M
Q2 25
$-6.0M
Q1 25
$-5.8M
Q4 24
$-4.7M
Q3 24
$-364.0K
Q2 24
$-3.1M
Q1 24
$-948.0K
FCF Margin
FTHM
FTHM
VRDN
VRDN
Q4 25
-22.8%
Q3 25
2.6%
-120.1%
Q2 25
-4.9%
Q1 25
-6.2%
Q4 24
-5.2%
Q3 24
-0.4%
Q2 24
-3.5%
Q1 24
-1.3%
Capex Intensity
FTHM
FTHM
VRDN
VRDN
Q4 25
0.1%
Q3 25
0.0%
0.2%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.1%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FTHM
FTHM

Real Estate Brokerage$84.9M94%
Mortgage Segment$3.4M4%
Other$2.3M3%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons